论文部分内容阅读
目的:分析探讨艾塞那肽治疗初诊2型糖尿病的临床疗效。方法:选取2014年4月至2015年10月期间来该院门诊部接受诊治的2型糖尿病患者82例,按照随机数字表法将82例患者分为两组,对照组41例,采用二甲双胍联合胰岛素对患者进行治疗,研究组41例,采用二甲双胍联合艾塞那肽对患者进行治疗,对比两组患者的临床疗效。结果:治疗后分别测定两组患者的体质量指数(BMI)、空腹血糖(FPG)、餐后2 h血糖(2 h FPG)、糖化血红蛋白(Hb A1C),可知研究组患者的体质量指数(BMI)和P2 h PG改善情况均明显优于对照组(P<0.05),两组患者的FPG和Hb A1C水平相近,无显著性差异(P>0.05)。结论:在2型糖尿病临床治疗上,艾塞那肽可有效控制患者的体重和血糖水平,具有一定的临床实用价值。
Objective: To investigate the clinical efficacy of exenatide in the treatment of newly diagnosed type 2 diabetes mellitus. Methods: From April 2014 to October 2015, 82 cases of type 2 diabetic patients who came to the outpatient department of our hospital for diagnosis and treatment were enrolled. 82 patients were divided into two groups according to the random number table method, and 41 patients in the control group were treated with metformin Insulin treatment of patients, the study group of 41 patients with metformin combined with exenatide on the treatment of patients, the clinical efficacy of two groups were compared. Results: Body mass index (BMI), fasting blood glucose (FPG), postprandial 2h FPG and Hb A1C were measured in two groups after treatment. The body mass index ( BMI and P2 h PG were significantly better than those of the control group (P <0.05). There was no significant difference between the two groups in the level of FPG and Hb A1C (P> 0.05). Conclusion: Exenatide can effectively control the body weight and blood glucose of type 2 diabetic patients and has certain clinical value.